Characteristics of 31 immunocompromised patients with protracted COVID-19 who received vax-plasma transfusion
| Characteristics (N = 31) . | Data . |
|---|---|
| Age, median (range), y | 63 (16-84) |
| Females/males, n | 11/20 |
| Hematological malignancies, n | 21∗ |
| CLL | 5 (24) |
| MCL | 5 (24) |
| MM | 4 (19) |
| AML | 2 (10) |
| DLBCL | 2 (10) |
| MALT lymphoma | 1 (5) |
| ALL | 1 (5) |
| FL | 1 (5) |
| Other immunosuppressive conditions, n | 12∗ |
| RA | 4 (33) |
| Systemic lupus erythematosus | 2 (17) |
| SOT† | 3 (25) |
| Multiple sclerosis | 1 (8) |
| CVID | 1 (8) |
| Brain tumor (DL-GNT) | 1 (8) |
| Active immunosuppressive treatment‡, n (%) | |
| Anti-CD20 therapy | 16 (52) |
| Bruton tyrosine kinase inhibitors | 5 (16) |
| CAR T-cell therapy | 3 (10) |
| COVID-19 severity (WHO score§ ) | |
| 3 | 2 (6) |
| 4 | 14 (45) |
| 5-6 | 12 (39) |
| 7 | 3 (10) |
| Previous COVID-19–specific treatments, n (%) | |
| Remdesivir | 30 (97) |
| Steroids | 26 (84) |
| mAb | 7 (23) |
| Vaccinated against SARS-CoV-2, n (%) | 21 (68) |
| Hospital admission, n (%) | |
| Inpatient | 29 (94) |
| ICU | 12 (39) |
| Overall survival, n (%) | 26 (84) |
| Characteristics (N = 31) . | Data . |
|---|---|
| Age, median (range), y | 63 (16-84) |
| Females/males, n | 11/20 |
| Hematological malignancies, n | 21∗ |
| CLL | 5 (24) |
| MCL | 5 (24) |
| MM | 4 (19) |
| AML | 2 (10) |
| DLBCL | 2 (10) |
| MALT lymphoma | 1 (5) |
| ALL | 1 (5) |
| FL | 1 (5) |
| Other immunosuppressive conditions, n | 12∗ |
| RA | 4 (33) |
| Systemic lupus erythematosus | 2 (17) |
| SOT† | 3 (25) |
| Multiple sclerosis | 1 (8) |
| CVID | 1 (8) |
| Brain tumor (DL-GNT) | 1 (8) |
| Active immunosuppressive treatment‡, n (%) | |
| Anti-CD20 therapy | 16 (52) |
| Bruton tyrosine kinase inhibitors | 5 (16) |
| CAR T-cell therapy | 3 (10) |
| COVID-19 severity (WHO score§ ) | |
| 3 | 2 (6) |
| 4 | 14 (45) |
| 5-6 | 12 (39) |
| 7 | 3 (10) |
| Previous COVID-19–specific treatments, n (%) | |
| Remdesivir | 30 (97) |
| Steroids | 26 (84) |
| mAb | 7 (23) |
| Vaccinated against SARS-CoV-2, n (%) | 21 (68) |
| Hospital admission, n (%) | |
| Inpatient | 29 (94) |
| ICU | 12 (39) |
| Overall survival, n (%) | 26 (84) |
Unless otherwise noted, data are presented as number (%).
ALL, Acute lymphoblastic leukemia; AML, acute myeloid leukemia; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; CVID, common variable immune deficiency; DLBCL, diffuse large B-cell lymphoma; DL-GNT, diffuse leptomeningeal disseminated glioneuronal tumor; FL, follicular lymphoma; ICU, intensive care unit; MALT, mucosa-associated lymphoid tissue; mAb, neutralizing antispike monoclonal antibodies; MCL, mantle cell lymphoma; MM, multiple myeloma; RA, rheumatoid arthritis; SOT, solid organ transplant; WHO, World Health Organization.
Note that hematological malignancies and other immunosuppressive conditions are not mutually exclusive. Two patients had multiple malignant diagnoses— CVID and MALT lymphoma (1 patient) and lupus and multiple kidney transplants (1 patient).
SOTs included heart (1 patient), both liver and kidney transplant (1 patient), and kidney transplant (1 patient).
Active immunosuppressive treatment included immunosuppressive treatment received any time during the 6 months before vax-plasma transfusion.
WHO Disease Severity Scale: 3, not hospitalized; 4, hospitalized, no supplemental oxygen; 5, hospitalized, nonhigh flow supplemental oxygen; 6, hospitalized, high flow supplemental oxygen; 7, hospitalized, intubated or extracorporeal membrane oxygenation; 8, deceased.